Polycystic ovary syndrome: current and future treatment paradigms (Q40831696)

24 September 2017

1 reference

title

Polycystic ovary syndrome: current and future treatment paradigms (English)

1 reference

polycystic ovary syndrome

24 September 2017

1 reference

1 reference

Legro RS

1

1 reference

PubMed ID

9855616

24 September 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

American Journal of Obstetrics and Gynecology

24 September 2017

1 reference

24 September 2017

179

1 reference

24 September 2017

6 Pt 2

1 reference

24 September 2017

S101-S108

1 reference

CLINICAL AND BIOCHEMICAL FEATURES OF POLYCYSTIC OVARIAN DISEASE.

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Polycystic ovaries--a common finding in normal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Observations on the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

The urinary excretion of interstitial-cell and follicle-stimulating hormone activity by women with diseases of the reproductive system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Inappropriate Secretion of Follicle-Stimulating Hormone and Luteinizing Hormone in Polycystic Ovarian Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Luteinizing Hormone Receptors in Ovarian Follicles of Patients with Polycystic Ovarian Disease*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Which hormone tests for the diagnosis of polycystic ovary syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Insulin resistance in nonobese patients with polycystic ovarian disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Insulin resistance in polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Characterization of obese women with reduced sex hormone-binding globulin concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Consensus Development Conference on Insulin Resistance. 5-6 November 1997. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Results from two national samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Acupuncture normalizes dysfunction of hypothalamic-pituitary-ovarian axis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Modern management of ovarian hyperstimulation syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Induction of ovulation with menotropins in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Fertility following bilateral ovarian wedge resection: a critical analysis of 90 consecutive cases of the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Impaired glucose tolerance, insulin resistance and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

A prospective study of oral contraceptives and NIDDM among U.S. women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Hormonal responses to physical exercise in patients with polycystic ovarian syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Obesity and polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Effects of exercise intensity on insulin sensitivity in women with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Hepatic dysfunction associated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

Hormonal effects of wedge resection of polycystic ovaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2898%2970240-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Randomised controlled trial of the use of human chorionic gonadotrophin in recurrent miscarriage associated with polycystic ovaries

1 reference

11 February 2024

https://opencitations.net/index/api/v1/citations/10.1111/J.1471-0528.1994.TB13185.X

Identifiers

DOI

10.1016/S0002-9378(98)70240-6

1 reference

24 September 2017

1 reference

PubMed ID

9855616